Ba 679 BR, A novel long-acting anticholinergic bronchodilator

https://doi.org/10.1016/0024-3205(93)90312-QGet rights and content

Abstract

The use of anticholinergics in antiobstructive therapy is well established in pulmonary medicine. We sought to improve the duration of action of inhaled antimuscarinics. A newly developed compound, Ba 679 BR (abbreviated Ba 679) proved to be a highly potent muscarinic antagonist in guinea pig tracheal rings. Its binding to human receptors (Hm1, Hm2, Hm3) was characterized by KD-values in the 10−10 M concentration range. Assessment of the dissociation rate of complexes of labelled Ba 679 and human muscarinic receptors revealed very slow dissociation in comparison to ipratropium. The half-lives in hours were: Ba 679-Hm3: 34.7, -Hm1: 14.6, -Hm2: 3.6; ipratropium-Hm3: 0.26, -Hm1: 0.11, -Hm2: 0.035. The duration of action in vivo was determined by means of acetylcholine-induced bronchospasms in dogs following inhalation of the drugs. Ba 679 demonstrated a significantly longer duration of protection than an equipotent dose of ipratropium. The plasma levels following inhalation in dogs declined rapidly and are unlikely to reflect the duration of the pharmacological activity.

In summary, Ba 679 represents a novel type of antimuscarinic bronchodilator with a long duration of action, most likely due to its slow dissociation from Hm3-receptors. In addition, the drug showed “kinetic receptor subtype selectivity” by having a more rapid dissociation from Hm2 than from Hm1 and Hm3 receptors.

References (11)

  • J.F.J. Morrison et al.

    Br. Med. J.

    (1988)
  • A. Engelhardt et al.

    Postgrad. Med. J.

    (1975)
  • H.J. Förster et al.

    Arzneim.-Forsch./Drug Res.

    (1976)
  • N.J. Gross

    Am. Rev. Respir. Dis.

    (1975)
  • G.M. Sterling

    Postgrad. Med. J.

    (1987)
There are more references available in the full text version of this article.

Cited by (167)

  • Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma

    2019, Bioorganic and Medicinal Chemistry Letters
  • Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus

    2018, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    Many studies suggest that the longevity of the antagonist-receptor complex is the cause of insurmountable antagonism, although the phenomenon has also been explained either by the presence of allosteric binding sites on the receptor or by the partitioning of the antagonist into (and slow removal from) tissue compartments or the matrix surrounding the receptor, which allows sustained release of the antagonist and increases the likelihood of rebinding to the receptor [35,36]. Several in vitro studies have found that the dissociation half-life at the human M3 muscarinic receptor (hM3R) is much longer for LAMAs that for ipratropium [9,10,12,19,37]. However, the experimental conditions in the in vitro evaluation of a drug's kinetic properties are less physiologically authentic than in an organ bath; tiotropium and glycopyrronium dissociate much more quickly from the hM3R at a physiological temperature and salt concentration (46 and 11 min, respectively) than in the receptor binding studies (462 and 173 min, respectively) [9,19].

  • Effects of tiotropium bromide on airway hyperresponsiveness and inflammation in mice exposed to organic dust

    2018, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    Thus, the model used in this study elicits similar effects as have previously been demonstrated in humans with a marked airway hyperresponsiveness and airway inflammation dominated by neutrophils. As tiotropium has a slow dissociation rate from the muscarinic receptors [14,15] the mice were treated with tiotropium one day before the three day exposure to OD. This regimen of tiotropium (0.002, 0.02 and 0.2 μg) administered intranasally caused a dose-dependent reduction of airway responsiveness to methacholine for both the control and the OD-exposed groups with respect to Newtonian resistance and tissue damping, but not for tissue elastance.

View all citing articles on Scopus
View full text